Skip to content
← Full study record

NCT00416884 · MORE INFO

Limitations, agreements, and source contact

Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML · Source last updated 2017-09-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
true
restrictive Agreement
false
limitations And Caveats
description
Study was terminated early due to low enrollment, hence the study did not have any treatment-related mortalities to report.
point Of Contact
organization
Center for Hematologic Malignancies
phone
503-494-1551
title
Center for Hematologic Malignancies
Complete source fields
certain Agreement
pi Sponsor Employee
true
restrictive Agreement
false
limitations And Caveats
description
Study was terminated early due to low enrollment, hence the study did not have any treatment-related mortalities to report.
point Of Contact
organization
Center for Hematologic Malignancies
phone
503-494-1551
title
Center for Hematologic Malignancies

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice